Citius Pharmaceuticals (CTXR) and its oncology-focused subsidiary, Citius Oncology (CTOR) announced that Lymphir has been assigned a unique, permanent Healthcare Common Procedure Coding System J-code by the Centers for Medicare & Medicaid Services. Effective April 1, healthcare providers may use the permanent J-code, J9161 when submitting claims for Lymphir. J-codes are unique identifiers utilized by U.S. government and commercial payers, as well as physicians and their office staff, to streamline the billing and reimbursement process for infused therapies and certain other treatments.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CTXR:
- CTXR Upcoming Earnings Report: What to Expect?
- Citius Pharmaceuticals announces $3M registered direct offering priced ATM
- Citius Pharmaceuticals and Citius Oncology to launch Lymphir in 1H25
- Citius Oncology to explore strategic alternatives
- Boeing slips after Jeju Air crash, HashiCorp-IBM draws review: Morning Buzz
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue